Skip to main content

Biologics include a wide range of products such as vaccines, blood and blood components, allergens, somatic cells, gene therapy, tissues and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the most widely used drugs for genetic disorders. New technologies, new therapies are emerging for the manufacture of new biological products, which represents a promising future for the market of biological products. Biologics are widely used to prevent, treat, diagnose, or cure various diseases, including cancer, chronic kidney disease, autoimmune disease, and infectious disease. Biologics are also used in the treatment of rare diseases in children, such as for the treatment of Batten disease, cerliponase alfa was first approved in 2017 by the US Food and Drug Administration (FDA) United.

Global Biologics Market: Drivers

The global biologics market is expected to experience significant growth during the forecast period, owing to the increase in product launches by key players such as Pfizer, Merck and Co. and GlaxoSmithKline (GSK). For example, Pfizer has a strong pipeline of vaccines, biosimilars, biologics and small molecules for 2019. The company has approximately 100 products in the trial phase, of which 35 are in phase 1, 28 are in phase 2, 26 in phase 3 and 11 in the registration process phase. The most recent was for Pfizer’s DAURISMO (glasdegib), which received US Food and Drug Administration (FDA) approval in November 2018. It was indicated for adult patients with newly diagnosed acute myeloid leukemia for which intensive chemotherapy is not a viable option. .

In addition, the global biologics market is growing rapidly, due to the increasing number of US FDA approvals for new biologics indicated for the treatment of rare diseases. For example, in December 2017, GlaxoSmithKline (GSK) received US FDA approval for its biologic “Nucala”, which is indicated for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA). Additionally, the US FDA approved approximately 46 additional biologics in 2017.

The main actors are : Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi SA, Eli Lilly & Company, Novo Nordisk A / S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen SA and Allergan Plc.

Regional analysis of the global organic products market

Among the regions, North America holds a dominant position in the world market for organic products. This is due to the strong presence of large biopharmaceutical and pharmaceutical companies in the United States, including Biogen Idec, Eli Lily and Compaby, AbbVie, GlaxoSmithKline, Amgen, Novartis, Johnson and Johnson, Sanofi and Pfizer. The increase in product approvals by regulatory authorities is expected to boost the market for organic products in North America. For example, in 2018, the United States FDA’s Center for Drug Evaluation and Research approved 59 new drugs and biologics and was launched in the United States.

In addition, Asia-Pacific is expected to show significant growth in the global biologics market, due to increased production of biosimilars from biologics. A biosimilar is generally a biological medical product, which is almost an identical copy of the original product made by another company. For example, Biocon Ltd., an Indian biopharmaceutical company, launched two biosimilars namely CANMAb (trastuzumad) and Krabeva (bevacuzumab) in India in 2017 and 2017. These biosimilars were indicated for the treatment of several types of cancer.

Request the PDF brochure of this report @

Global organic market: taxonomy

The global organic market is segmented on the basis of product type, application, end user, and region.

By product type

  • Monoclonal antibodies
  • Vaccines
  • Hormones / recombinant proteins
  • Cell therapy
  • Genetical therapy

By application

  • Oncology
  • Infectious diseases
  • Immunology
  • Autoimmune diseases
  • Others

Distribution channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

By region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

The organic products market is emerging as one of the most lucrative businesses in the world. The market has shown considerable growth figures driven by abundance of raw materials, increasing population, expansion of regions, rapid increase in demand and advanced technologies. The report should be executed vigorously in the coming phase, analysts predicted after surveying the market at an insignificant level.

Various analytical tools such as SWOT, Feasibility Analysis, Porter’s Five Forces Analysis, Value Chain Analysis, and Capacity Utilization Analysis are implemented while assessing the Biologics Market , which certainly helps a reader gain a deeper insight into the market and its participants. In addition, it covers a cardinal assessment of market history, patterns, changing dynamics, market and manufacturing trends, demand and supply activities, and technology development.

About Coherent Market Insights

Coherent Market Insights is a leading market research and consulting firm providing action-ready syndicated research reports, personalized market analysis, advisory services and competitive analysis through various recommendations related to emerging market trends , technologies and potential opportunities in absolute dollars.

Contact us

Mr. Shah
Consistent market information
1001 4th avenue, # 3200
Seattle, Washington 98154
Phone: United States +12067016702 / United Kingdom +4402081334027
Email: [email protected]

Leave a Reply